Braxia Scientific Appoints Dr David Greenberg to Board of Directors

TORONTO, May 31, 2021 / PRNewswire / – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research-driven clinical platform developing and providing innovative ketamine treatments for people with depression and disorders partners, is pleased to announce that it has appointed Dr. David Greenberg to its board of directors.

Nationally recognized general practitioner for over 30 years and lecturer at The University of Toronto in the Department of Family and Community Medicine, Dr. David Greenberg brings extensive experience in mental health and concussion. He has developed and implemented several training programs for physicians, nationally and internationally, and is considered an international health expert and keynote speaker on the topic of depression and related disorders.

Dr Greenberg is a team physician for the Toronto Argonauts, Canadian Football League, and a member of the ECHO Concussion Program (ECHO) Expert Panel at the University Health Network. The ECHO Concussion Program is an interactive medical education program, connecting healthcare providers with a team of interprofessional specialists to advance learning and enhance clinical skills. There are over 330 ECHO hubs in 37 countries, including United States, United Kingdom and Australia and is internationally recognized for its innovative research and best practices in the field of concussion and related conditions. Dr Greenberg is also a member of the Center for Effective Practice, a working group with a general interest in improving best practices and implementing primary care for concussions.

“We are delighted to welcome Dr. Greenberg to the Board as we establish Braxia as a leader in setting the standard of mental health care for depression and as we expand our clinical platform to support the development of new ketamine-based and psychedelic drugs in Canada and United States“Said Dr. Roger mcintyre, CEO of Braxia Scientific. “Dr. Greenberg’s extensive experience and network within the North American and international health community, particularly in the areas of mental health and concussion and with professional athletes, among others, will be a significant advantage. as we continue to develop and implement breakthrough ketamine treatments. and protocols that will result in better results for the patients who come to our clinics. ”

Dr. Greenberg consults with various companies on sales, marketing, communications and business development strategies. He was previously president of Goldfarb Health Care, which was From Canada largest market research firm during his tenure. He has continued to work with healthcare related companies over the years, providing expert advice and information on the beliefs, values ​​and behaviors of consumers and physicians in order to develop educational programs, relationships very effective publicity and sales and marketing strategies. Dr Greenberg is a Mentor at the Creative Destruction Lab at the Rotman Business School of University of Toronto and the Said Business School at Oxford University. Through this incubator program, he mentors founders who seek business opportunities based on translational scientific and technological innovations that improve human health and well-being.

Dr Greenberg is a member of the ProSpeakers Bureau, an organization which is a trusted and trusted resource for renowned speakers, and continues to be a corporate spokesperson for various organizations.

Dr. Greenberg has gained a national reputation for effectively conveying highly complex questions and concepts in a simple and entertaining manner. He was resident GP on “The Mom Show” (5 seasons), CityLine (9 seasons) and host of his own show “Dr. in The House” (2 seasons), as well as numerous other appearances in media like “Dr Dave”.

Grant of stock options

The company also announced that it has granted stock options to certain of its directors, officers, employees and consultants to acquire a total of 9,750,000 common shares of the company. Each option may be exercised against one ordinary share of the company at an exercise price of $ 0.395 per share, i.e. the closing price of the shares on the Canadian Stock Exchange May 28, 2021, for a five-year term expiring on May 28, 2026. Subject to certain accelerated vesting provisions, one-third of the options will vest immediately, one-third will vest after 12 months and the remaining third will vest 18 months after the date of grant.

Media service engagement

The Company is pleased to announce that it has retained the services of Stock Day Media to provide media services. Under the terms of the deal, Stock Day Media will feature the company on its podcasts and provide a combination of news distribution and campaign reporting at a total cost of 12,000 USD over a planned period of three months, subject to renewal.

About Braxia Scientific Corp.

Braxia Scientific is a research-driven medical solutions company that aims to reduce the disease burden of brain-related mental disorders such as major depressive disorder, among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to the discovery and commercialization of new drugs and methods of administration. The company is developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community clinics providing treatment to Mississauga, Toronto, Ottawa, and Montreal.


“Dr. Roger S. McIntyre
Dr. Roger S. McIntyre
Chairman and CEO

The CSE has not reviewed and accepts no responsibility for the accuracy or adequacy of this release.

Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking statements include statements about the expected promise of ketamine and esketamine treatments for depression, and the potential of ketamine to treat other emerging psychiatric disorders, in order for the company to be a leader in this area and for the company’s ability to develop its clinical network. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from any future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine to provide the expected health benefits and unintended side effects, dependence on obtaining and maintaining regulatory approvals, including acquisition and renewal federal, provincial, municipal, local or other licenses and participation in activities. which could later be found to be illegal under national or international law. These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements. Although the Company has attempted to identify material risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results differ from those anticipated, estimated or expected. Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, available on There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

SOURCE Braxia Scientific Corp.

Related links

Source link

About Margie Peters

Check Also

Depression, anxiety associated with osteocalcin, cortisol in hyperparathyroidism

Serum cortisol and osteocalcin levels may be associated with symptoms of anxiety and depression in …

Leave a Reply

Your email address will not be published. Required fields are marked *